🇺🇸 FDA
Patent

US 8748597

2,4-pyrimidinediamine compounds and their uses

granted A61KA61K31/505A61K31/506

Quick answer

US patent 8748597 (2,4-pyrimidinediamine compounds and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jun 10 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K31/505, A61K31/506, A61K31/519, A61K31/5377